Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a drop in COVID-19 vaccine sales.
Net income decreased by 70% to $1.5 billion while EPS dropped by 68% to $3.61 compared to the same period last year.
The company expects product sales of approx. $2 billion in the first half of 2023.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
After mixed Q2, what awaits Apple (AAPL) in the second half?
Apple’s (NASDAQ: AAPL) stock rallied this week after the gadget giant reported stronger-than-expected Q2 results and announced the largest-ever share buyback program. The company is investing heavily in the business,
What to expect when Tyson Foods (TSN) reports Q2 2024 earnings results
Shares of Tyson Foods, Inc. (NYSE: TSN) stayed green on Friday. The stock has gained 8% over the past three months. The branded foods company is slated to report its
EXPE Earnings: Expedia reports adj. profit for Q1; revenue rises 8%
Expedia Group (NASDAQ: EXPE) has reported an increase in revenues for the first quarter of 2024. The travel company turned to net profit in Q1, on an adjusted basis, from
